Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAD for Preventing Myocardial Injury in Pneumonia
NCT06296212Phase 3Recruiting
- Sponsor
- Biomedica Foscama S.p.A.
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of thioguanine + cytarabine + daunorubicin in Myocardial injury, sponsored by Biomedica Foscama S.p.A.. Started Jun 2024; status: recruiting.
02
Drugs
thioguanine + cytarabine + daunorubicin
03
Conditions
Myocardial injury
Beyond the preview
Go deeper on NCT06296212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06296212.